What Hurts Dermatology Practice Business Valuations?

Owner dependency cuts 2 to 3 turns off a dermatology practice multiple — the single biggest drag on value — dropping otherwise strong practices from 8.0x-12.0x EBITDA down to 3.5x-5.0x when the physician-owner performs 60%+ of treatments. Medicaid exposure above 20% costs another 0.5x to 1.0x. Buyers like US Dermatology Partners, Schweiger Dermatology, Forefront Dermatology, and DOCS Dermatology Group underwrite transferability, not just profit.

Key Data

  • Owner-dependent discount: 3.5x–5.0x EBITDA (vs. 8.0x–12.0x for scaled platforms)
  • Medicaid exposure haircut: 0.5x–1.0x off multiple above 20% mix
  • PE platforms: 35+ backed dermatology platforms across ~20 states

The Biggest Single-Factor Drag: Owner Concentration

The fastest way to lose 2 to 3 turns on your multiple is to be the physician who sees most of the patients. When the owner performs 60% or more of treatments, buyers assume revenue walks out the door at close — and they're usually right. That structural risk is baked into every term sheet I've seen from PE-backed platforms. Even if your practice generates $1.2M in EBITDA, a single-physician, single-location model clears closer to 3.5x to 5.0x, not the 8.0x-plus that gets quoted in market reports. Practices with a layered team of dermatologists, PAs, and NPs who carry their own panels trade dramatically higher because the cash flow survives the sale. If you want context on what full-price practices look like, the dermatology valuation hub walks through the tiers in detail.

Payer Mix, Growth Visibility, and Compliance Flags

After owner dependency, the three next-largest drags are payer mix, growth trajectory, and compliance. Medicaid exposure above 20% will cost you 0.5x to 1.0x on the multiple because buyers model rate-cut risk directly into returns. A practice with flat or declining patient volume over the last 18 months gets underwritten for future decline, not stability. And any open coding audit, billing irregularity, or documentation gap discovered in diligence — I've seen it happen — either collapses the deal or re-prices it 20–30% lower. Dermatology compliance standards have tightened as PE platforms build out, and the related specialty expectations show up across other PE-backed medical specialties too.

"I worked with a dermatologist last year who did $1.1M in EBITDA and thought he'd get 9x because that's what the reports said. Every platform we talked to came back between 4.5x and 5.2x — because he did 72% of procedures himself and Medicaid was 28% of his book. We spent 14 months onboarding a second derm and a PA-led medical track, and the re-trade closed at 6.8x. The market pays for transferability. It doesn't pay for how good you personally are."

Frequently Asked Questions

The Biggest Single-Factor Drag: Owner Concentration
The fastest way to lose 2 to 3 turns on your multiple is to be the physician who sees most of the patients. When the owner performs 60% or more of treatments, buyers assume revenue walks out the door at close — and they're usually right. That structural risk is baked into every term sheet I've seen from PE-backed platforms. Even if your practice generates $1.2M in EBITDA, a single-physician, single-location model clears closer to 3.5x to 5.0x, not the 8.0x-plus that gets quoted in market reports. Practices with a layered team of dermatologists, PAs, and NPs who carry their own panels trade dramatically higher because the cash flow survives the sale. The gap between 'the business' and 'the doctor' is the single biggest line item in a diligence model.
Payer Mix, Growth Visibility, and Compliance Flags
After owner dependency, the three next-largest drags are payer mix, growth trajectory, and compliance. Medicaid exposure above 20% will cost you 0.5x to 1.0x on the multiple because buyers model rate-cut risk directly into returns. A practice with flat or declining patient volume over the last 18 months gets underwritten for future decline, not stability. And any open coding audit, billing irregularity, or documentation gap discovered in diligence — I've seen it happen — either collapses the deal or re-prices it 20-30% lower. Dermatology compliance standards have tightened as PE platforms build out, and buyers are increasingly willing to walk from deals rather than work through ambiguous billing. Clean, documented compliance is worth real dollars, and it's the cheapest multiple-booster most sellers ignore.